Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients

Table 1

Demographic and examination data of both groups.

		Group A	Group B	value
		(Chloroquine group)	(Control group)
Age in years	Mean ± SD	49.95 ± 7.78	51 ± 7.38	0.49
BCVA (LogMAR)	Mean ± SD	0.3688 ± 0.307	0.4825 ± 0.343	0.122
Color vision (normal/defective)	Normal	(34/6)	(36/4)	0.499
Disease duration in years	Mean ± SD	8.1 ± 7.67	N/A	—
Chloroquine treatment Duration in years	Mean ± SD	3.8 ± 2.79	N/A	—
Chloroquine cumulative dose (grams)	Mean ± SD	346.6 ± 225.24	N/A	—

Independent samples student’s -test.
Chi square test.